CSUI: AI 评分 39/100 — AI 分析 (4月 2026)

Cannabis Suisse Corp. operates in the healthcare sector, focusing on the production and distribution of over-the-counter products, recreational tobacco, and medical CBD oils. The company utilizes its Swiss4Life brand and a network of retailers to reach consumers.

Key Facts: AI Score: 39/100 Sector: Healthcare

公司概况

概要：

Cannabis Suisse Corp. is a healthcare company focused on over-the-counter products, recreational tobacco, and medical CBD oils, distributed through its Swiss4Life brand and a retail network. With a high profit margin but negative gross margin, the company operates in a competitive and evolving market landscape.

CSUI是做什么的？

Cannabis Suisse Corp., formerly Geant Corp., was established in 2016 and rebranded in February 2019 to reflect its focus on cannabis-related products. Headquartered in Bell Gardens, California, the company cultivates, produces, and distributes a range of products including over-the-counter health supplements, recreational tobacco products, and medical CBD oils. Its primary retail channel is Swiss4Life, an online brand, supplemented by a network of retailers. The product line extends beyond cannabis-related items to include health-related supplements, face masks, disinfectants, and traditional cigarettes. This diversified approach aims to capture a broader market segment within the health and wellness sector. The company's strategy involves leveraging both direct-to-consumer online sales and established retail partnerships to enhance market penetration and brand visibility. Cannabis Suisse Corp. operates within the evolving regulatory landscape of the cannabis industry, adapting its business model to comply with local and international laws.

CSUI的投资论点是什么？

Cannabis Suisse Corp. presents a complex investment profile. While the company boasts a high profit margin of 1469.1%, its negative gross margin of -54.7% raises concerns about operational efficiency and cost management. The company's focus on over-the-counter products, recreational tobacco, and medical CBD oils positions it in a market with both growth potential and regulatory uncertainty. Key value drivers include the expansion of its Swiss4Life brand and the establishment of strategic retail partnerships. Upcoming regulatory changes in the cannabis industry could significantly impact the company's operations and profitability. Investors should closely monitor the company's ability to improve its gross margin and navigate the evolving regulatory landscape.

CSUI在哪个行业运营？

Cannabis Suisse Corp. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The industry is characterized by intense competition, evolving regulatory landscapes, and increasing consumer demand for health and wellness products. Market trends include the growing acceptance of CBD products and the legalization of cannabis in various jurisdictions. Cannabis Suisse Corp. competes with established pharmaceutical companies and emerging cannabis businesses, navigating a complex environment of regulatory compliance and market differentiation. The company's success depends on its ability to innovate, adapt to changing regulations, and effectively market its products to a diverse consumer base.

Drug Manufacturers - Specialty & Generic

Healthcare

CSUI有哪些增长机遇？

Expansion of Swiss4Life Brand: Cannabis Suisse Corp. can leverage its Swiss4Life brand to expand its online presence and direct-to-consumer sales. The global e-commerce market is projected to reach trillions of dollars in the coming years, offering a significant opportunity for growth. By investing in digital marketing and enhancing its online platform, the company can attract new customers and increase brand loyalty. Timeline: Ongoing.
Strategic Retail Partnerships: Establishing partnerships with major retailers can significantly expand Cannabis Suisse Corp.'s distribution network and market reach. The retail industry is evolving, with consumers increasingly seeking health and wellness products in convenient locations. By securing shelf space in established retail chains, the company can increase product visibility and drive sales. Timeline: Ongoing.
Product Diversification: Expanding the product line to include new and innovative health and wellness products can attract a broader customer base and increase revenue streams. The health and wellness market is constantly evolving, with new trends and consumer demands emerging regularly. By investing in research and development, Cannabis Suisse Corp. can create unique and differentiated products that meet the needs of its target market. Timeline: Ongoing.
Geographic Expansion: Entering new geographic markets can significantly increase Cannabis Suisse Corp.'s growth potential. The global cannabis market is expanding rapidly, with new countries and regions legalizing cannabis for medical and recreational use. By carefully selecting target markets and adapting its products to local regulations and consumer preferences, the company can capitalize on this growth opportunity. Timeline: Upcoming.
Regulatory Changes: Upcoming changes in cannabis regulations could create new opportunities for Cannabis Suisse Corp. As more jurisdictions legalize cannabis, the company can expand its operations and enter new markets. By staying informed about regulatory developments and adapting its business model accordingly, Cannabis Suisse Corp. can capitalize on these opportunities and gain a competitive advantage. Timeline: Ongoing.

Profit Margin of 1469.1% indicates high profitability, but needs further investigation into the drivers and sustainability.
Negative Gross Margin of -54.7% signals potential issues with cost of goods sold and pricing strategies.
Market Cap of $0.00B indicates the company is a micro-cap stock with high volatility and risk.
P/E Ratio of 7.70 suggests the stock may be undervalued compared to its earnings, but should be considered alongside other financial metrics.
Beta of -4.65 indicates the stock is negatively correlated with the market, which may offer diversification benefits but also reflects unique company-specific risks.

CSUI提供哪些产品和服务？

Cultivates and produces over-the-counter products.
Manufactures and distributes recreational tobacco products.
Produces and sells medical CBD oils.
Sells products through the Swiss4Life online retail brand.
Distributes products through a network of retailers.
Offers health-related supplements.
Provides face masks and disinfectants.
Retails cigarettes.

CSUI如何赚钱？

Cultivation and production of cannabis-related products.
Direct-to-consumer sales through the Swiss4Life online platform.
Distribution through a network of retail partners.
Sales of health-related supplements and other wellness products.

Consumers seeking over-the-counter health and wellness products.
Individuals interested in recreational tobacco products.
Patients seeking medical CBD oils for therapeutic purposes.
Online shoppers through the Swiss4Life platform.
Retail customers through the company's network of retail partners.

Established Swiss4Life online retail brand.
Network of retail distribution partners.
Diversified product line including cannabis-related and health-related products.
Early mover advantage in the emerging cannabis market.

什么因素可能推动CSUI股价上涨？

Ongoing: Expansion of the Swiss4Life brand through digital marketing and e-commerce initiatives.
Ongoing: Strategic partnerships with major retailers to expand distribution network.
Ongoing: Product diversification to include new and innovative health and wellness products.
Upcoming: Potential changes in cannabis regulations that could create new market opportunities.
Ongoing: Geographic expansion into new and emerging cannabis markets.

CSUI的主要风险是什么？

Ongoing: Intense competition from established pharmaceutical companies and emerging cannabis businesses.
Ongoing: Evolving regulatory landscape and potential changes in cannabis laws.
Potential: Fluctuations in commodity prices and supply chain disruptions.
Potential: Negative public perception and potential health concerns related to cannabis and tobacco products.
Ongoing: Negative gross margin indicating potential issues with cost management.

CSUI的核心优势是什么？

Established Swiss4Life online retail brand.
Diversified product line including cannabis-related and health-related products.
Early mover advantage in the emerging cannabis market.
High reported profit margin (though offset by negative gross margin).

CSUI的劣势是什么？

Negative gross margin indicates potential issues with cost management.
Limited market capitalization and potential liquidity concerns.
Reliance on a relatively new and evolving regulatory landscape.
Limited brand recognition compared to larger competitors.

CSUI有哪些机遇？

Expansion of the Swiss4Life brand through digital marketing and e-commerce initiatives.
Strategic partnerships with major retailers to expand distribution network.
Product diversification to include new and innovative health and wellness products.
Geographic expansion into new and emerging cannabis markets.

CSUI面临哪些威胁？

Increasing competition from established pharmaceutical companies and emerging cannabis businesses.
Evolving regulatory landscape and potential changes in cannabis laws.
Fluctuations in commodity prices and supply chain disruptions.
Negative public perception and potential health concerns related to cannabis and tobacco products.

CSUI的竞争对手是谁？

Canna-Global Acquisition Corp — Focuses on cannabis cultivation and processing. — (CNTRF)
Elixinol Wellness Ltd — Specializes in CBD products and wellness solutions. — (ELLXF)
Industrial Development Corp. — Engages in industrial development, potentially including cannabis-related projects. — (IDCN)
Mountain Smokes Companies Inc — Focuses on tobacco and hemp-based smokable products. — (MSMY)
New Green Mountain Corp. — Operates in the cannabis and hemp industries. — (NGMC)

Key Metrics

MoonshotScore: 39/100

Company Profile

CEO: Scott W. Mcalister
Headquarters: Jacksonville, US
Founded: 2019

AI Insight

AI analysis pending for CSUI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cannabis Suisse Corp. do?

Cannabis Suisse Corp. cultivates, produces, and distributes a range of products including over-the-counter health supplements, recreational tobacco products, and medical CBD oils. The company sells its products through its Swiss4Life online retail brand and a network of retail partners. This diversified approach allows the company to target a broad customer base within the health and wellness sector, while navigating the evolving regulatory landscape of the cannabis industry. The company's focus on both direct-to-consumer sales and retail partnerships aims to maximize market penetration and brand visibility.

What do analysts say about CSUI stock?

There is currently no available analyst coverage for Cannabis Suisse Corp. (CSUI). Given its OTC listing and micro-cap status, the company may not be actively tracked by major brokerage firms. Investors should conduct their own independent research and due diligence before making any investment decisions. Key valuation metrics to consider include the company's profit margin, gross margin, and revenue growth potential. The evolving regulatory landscape of the cannabis industry also presents both opportunities and risks for the company.

What are the main risks for CSUI?

Cannabis Suisse Corp. faces several key risks, including intense competition from established pharmaceutical companies and emerging cannabis businesses. The evolving regulatory landscape of the cannabis industry also presents significant uncertainty. Fluctuations in commodity prices and potential supply chain disruptions could impact the company's profitability. Additionally, negative public perception and potential health concerns related to cannabis and tobacco products could affect consumer demand. The company's negative gross margin also poses a significant risk, indicating potential issues with cost management and pricing strategies.